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Abstract
Background: Uterine adenosarcomas are rare malignant gynaecological tumours. Due to its submucous
localization, they can be easily confound with benign tumours like endometrial polyps or submucous myomas.
However, the treatment of uterine adenosarcomas requires an oncologic surgical approach.
Case presentation: In the following case report, we present the minimally invasive treatment of a uterine
adenosarcoma by hysteroscopy and laparoscopy in a 37-year-old patient and discuss the special role of
hysteroscopy in such cases.
Conclusions: In case of unknown or suspect intrauterine tumours, a diagnostic and operative hysteroscopy with
biopsy could be realized prior to laparoscopic hysterectomy especially when the use of a laparoscopic electric
morcellation is planned. Thus, a correct oncologic approach can be guaranteed if an adenosarcoma is diagnosed.
Trial registration: ISRCTN
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Background
Uterine adenosarcomas are rare mixed epithelial-
mesenchymal tumours and account for approximately 8 %
of all uterine sarcomas. Following the WHO classification,
they histologically belong to the same group as carcinosar-
comas, carcinofibromas and the benign conditions adenofi-
bromas and adenomyomas. Uterine adenosarcomas can be
found in all age classes. Gallardo et al. reported a mean
patient age of 50 years in 55 cases of adenosarcomas [1].
Most of the adenosarcomas can be found not only in the
uterine corpus but also in the cervix, the ovaries, the fallo-
pian tubes, vagina and peritoneum. The uterine tumours
clinically appear as submucous polypoid masses with abnor-
mal uterine bleeding and can be easily confound with polyps
or myomas in preoperative ultrasound and diagnostic hys-
teroscopy. Definitive diagnosis of an adenosarcoma is usually
achieved only after pathologic examination of the surgical
specimen. We present our course of action in a case of a
premenopausal patient with a submucous adenosarcoma
and discuss the role of diagnostic and operative hysteros-
copy in case of uncertain submucous lesions in order to
avoid hysterectomy with laparoscopic electric morcellation
in adenosarcoma and thus assure an oncologically correct
approach in this rare condition.
Case presentation
The 37-year-old patient attended with recurrence of
bleeding disorders under oral contraception. The ultra-
sound examination revealed endometrial hyperplasia. A
diagnostic-operative hysteroscopy with uterine abrasion
was indicated. The patient gave written informed con-
sent. Hysteroscopy showed a submucous tumour in the
left uterine cavity comparable to a submucous polyp or
myoma Typ 0 (Fig. 1). We resected the tumour by bipo-
lar hysteroresectoscopy evacuating all tissue fragments
from the uterus. The histological examination revealed
an epithelial-mesenchymal lesion. Immunohistologically,
the epithelial part of the tumour expressed MNF116,
while the mesenchymal fraction expressed CD10 and
actin. The final diagnosis was an adenosarcoma of the
uterine corpus. Although the tumour had been resected
completely (R0) by hysteroscopy, we subsequently
performed a laparoscopic hysterectomy without power
morcellation combined with bilateral salpingectomy,
unilateral oophorectomy, a biopsy of the contralateral
ovary, peritoneal biopsies and intraperitoneal cytology.
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No more parts of the adenosarcoma could be found; thus,
finally, a low-grade adenosarcoma FIGO stage I was diag-
nosed. After 4 months, the patient presented with pelvic
pain and a cystic ovarian process. Laparoscopy revealed a
benign functional ovarian cyst and peritoneal adhesions,
but no evidence of recurrence of the adenosarcoma.
Discussion
Early diagnosis in uterine adenosarcoma is essential be-
cause patients’ survival is correlated to the tumour stage.
Preoperative physical examination combined with trans-
vaginal ultrasound is not suspicious in most of the cases
[2]. Usually, definitive diagnosis of adenosarcoma is
achieved only after surgical specimen analysis. Only
diagnostic hysteroscopy with intrauterine biopsy or re-
section allows the histological evaluation of the tumour
before definitive hysterectomy and thus a subsequent
correct oncologic approach in case of a malignant
process. Therefore, especially when hysterectomy with
electric morcellation is planned, a hysteroscopy with bi-
opsy could be performed in case of premenopausal sub-
mucous lesions in order to differ malignant lesions from
benign polyps or myomas. Gonzalez-Bosquet et al. re-
ported one case of hysteroscopic detection of a uterine
adenosarcoma in a postmenopausal woman [3] and the
diagnosis of an endometrial stromal sarcoma in a 41-
year-old woman who presented with bleeding disorders
and polypoid masses in ultrasound [4]. Shveiky et al. [5]
reported six cases of unexpected malignant uterine mes-
enchymal tumours. In all cases, the initial hysteroscopic
diagnosis erroneously was endometrial polyp or submu-
cous myoma: only pathology revealed the malignancy of
the lesions, and thus, all patients underwent complete
staging by laparotomy. None of the patients had extrauter-
ine spread of the disease, and at mean follow-up of
21.5 months, all patients were asymptomatic. It plays an
important role if the adenosarcoma shows a sarcomatous
overgrowth or not. A sarcomatous overgrowth is diagnosed
when more than 25 % of the tumour volume is sarcoma-
tous tissue. Gallardo reported that sarcomatous overgrowth
was found in 33 % of uterine adenosarcomas. Six out of 29
patients with adenosarcoma developed metastasis. Four of
these six patients had adenosarcomas with sarcomatous
overgrowth [1]. Schroeder et al. described a systemic ther-
apy in advanced uterine adenosarcoma with sarcomatous
overgrowth [6]. Tissue with sarcomatous overgrowth can
be detected by immunohistochemical analysis, while the
differentiation between adenosarcomas without sarcoma-
tous overgrowth and benign adenofibromas can be difficult.
However, a standardized therapeutic approach for adeno-
sarcoma is not yet established. Usually, the treatment is
analogue to the therapy of the endometrial stromal sar-
coma. In postmenopausal women, the hysterectomy with
bilateral adnexectomy and peritoneal staging is the treat-
ment of first choice. In comparison, in premenopausal
women, it is possible to save the ovaries. The lymphadenec-
tomy is not established, due to the low rate of lymphatic
metastasis. In addition, the lymphatic node status would
have no consequence for the adjuvant treatment, as a spe-
cific chemotherapy does not exist. Clement et al. reported
that radiotherapy has no benefit for the patient in case of
adenosarcomas [7]. However, Kaku et al. described that in
31 % of all cases, an extrauterine manifestation of the
tumour can be found in the vagina, the lymphatic nodes,
the peritoneal cytology or the ovary [8]. In this case of low-
grade adenosarcoma without adenosarcomatous over-
growth, we preferred the minimally invasive approach for
hysterectomy and staging, as laparotomy has many well-
known disadvantages but no benefit in order to carry out a
simple hysterectomy with adnexectomy and peritoneal sta-
ging. Further studies must show if there is a difference in
the prognosis of the disease comparing laparoscopy to lapar-
otomy when staging is realized. It also remains unclear if
bilateral adnexectomy should be part of the surgical staging
in uterine adenosarcoma. However, in low-grade and high-
grade endometrial stromal sarcoma, the bilateral adnexect-
omy is recommended [9], but ovary-sparing procedures
could be considered for young women [10]. In this case of a
premenopausal woman, we decided to preserve one ovary
and thus the hormonal function. A representative laparo-
scopic ovarian biopsy did not show any remaining micro-
scopic disease. A second-look laparoscopy after 4 month for
ovarian tumour revealed a benign functional cyst.
The main risk factors for recurrence and metastasis in
uterine sarcomas are the myometrial infiltration, the
tumour size, the extrauterine appearance, the histological
tumour type and the presence of sarcomatous overgrowth
[8]. The recurrence rate in adenosarcoma without sar-
comatous overgrowth is estimated to be 15–25 % respect-
ively and 45–70 % in cases with sarcomatous overgrowth.
On a multivariate analysis, Carroll et al. [11] showed that
sarcomatous overgrowth and lymphovascular space
Fig. 1 Submucous uterine adenosarcoma in diagnostic hysteroscopy
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invasion were predictors of worse progression-free sur-
vival and overall survival. Another important prognostic
factor is the complete resection (R0) of the sarcoma with-
out intra-abdominal morcellation of the sarcoma. In mod-
ern gynaecological minimally invasive surgery, the electric
morcellation of uterine tissue in laparoscopic myomec-
tomy or total and subtotal hysterectomy plays an import-
ant technical role. The risk of accidental morcellation of
occult sarcoma is currently under discussion [12–14]. The
incidence of this rare complication has to be shown by fur-
ther studies but is estimated to be under 1 %. The steering
committee on fibroid morcellation of the European Society
of Gyneacological Endoscopy (ESGE) concluded that the
prevalence of uterine sarcoma in presumed fibroids is
0.14 % with a range from 0.49 to 0.014 % [15]. However,
the patients should be informed about this risk when the
use of morcellation is planned and alternative surgical ap-
proaches should be discussed. While the intraperitoneal
morcellation of submucous uterine sarcomas influences the
prognosis of the disease, the role of intrauterine biopsy or
resection of adenosarcoma in hysteroresectoscopy on the
prognosis of the disease so far remains unclear. In compari-
son, in endometrial cancer, the diagnostic hysteroscopy
with biopsy or curettage is a standard procedure and the
eventual diversion of cancer cells with the distension
medium through the fallopian tubes to the peritoneal cavity
is not seen as a risk factor [16]. As adenosarcomas are rare
tumours, it will be difficult to achieve reliable prospective
data in studies. A second-look laparoscopy after 6 to
12 months could be an option in order to offer the maximal
surgical safety to the patient. It is very important to avoid
perforation of the uterine wall in the diagnostic or operative
hysteroscopy as a peritoneal metastasis could be the result
in case of a malignant lesion.
Conclusions
Submucous adenosarcomas in premenopausal women are
rare malignant tumours and can be easily confound with
benign endometrial polyps or submucous myomas. A pre-
surgical differentiation by ultrasound is not possible. In
order to avoid an oncologically incorrect approach, a diag-
nostic hysteroscopy with possible consecutive biopsy could
be performed in case of submucous uterine tumours when
hysterectomy with electric morcellation is planned. Further
studies could show if the intrauterine morcellation by hys-
teroresectoscopy of submucous adenosarcomas has any in-
fluence on the prognosis of the disease due to the possible
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